A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa)

被引：0
|
作者：
Kilari, D. [1 ]
Guancial, E. [2 ]
Sahasrabudhe, D. [2 ]
Bylow, K. [1 ]
Sievert, L. [2 ]
Schaffer, K. [2 ]
Riese, M. [1 ]
Burfeind, J. [1 ]
Musto, K. [1 ]
Feng, C. [3 ]
Messing, E. [4 ]
Mohile, S. [2 ]
Fung, C. [2 ]
机构：
[1] Med Coll Wisconsin, Froedtert Hosp, Med, Milwaukee, WI 53226 USA
[2] Univ Rochester, Med, Rochester, NY USA
[3] Univ Rochester, Biostat, Rochester, NY USA
[4] Univ Rochester, Urol, Rochester, NY USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
808P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa).
    Kilari, Deepak
    Cuancial, Elizabeth A.
    Sahasrabudhe, Deepak M.
    Bylow, Kathryn A.
    Burfeind, John D.
    Musto, Kaylinn
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [2] A phase II study of enzalutamide (Enz) with dutasteride (Dut) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Final analysis
    Kilari, D.
    Zittel, J.
    Patel, A.
    Sahasrabudhe, D.
    Feng, C.
    Burfeind, J.
    Guancial, E.
    Messing, E.
    Bylow, K.
    Mohile, S.
    Fung, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S540 - S541
  • [3] A phase II study of enzalutamide (Enz) with dutasteride (Out) or finasteride (Fin) in men ≥ 65 years with hormone-naive systemic prostate cancer (HNSPCa): Tolerability and geriatric asssessment (GA) results.
    Zittel, Jason
    Fung, Chunkit
    Babu, Dilip Sankar
    Guancial, Elizabeth A.
    Sahasrabudhe, Deepak M.
    Bylow, Kathryn A.
    Burfeind, John D.
    Musto, Kaylinn
    Wang, Bokai
    Patil, Amita
    Messing, Edward M.
    Mohile, Supriya Gupta
    Kilari, Deepak
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [4] Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Heidenreich, Axel
    Iversen, Peter
    Baskin-Bey, Edwina S.
    Perabo, Frank
    Phung, De
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [5] Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    Phung, De
    Smith, Matthew R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [6] A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-Naive Metastatic Prostate Cancer
    Corn, Paul G.
    Zhang, Miao
    Nogueras-Gonzalez, Graciela M.
    Xiao, Lianchun
    Zurita, Amado J.
    Subudhi, Sumit K.
    Tu, Shi-Ming
    Aparicio, Ana M.
    Coarfa, Cristian
    Rajapakshe, Kimal
    Huang, Shixia
    Navone, Nora M.
    Lin, Sue-Hwa
    Wang, Guocan
    Ramachandran, Sumankalai
    Titus, Mark A.
    Panaretakis, Theocharis
    Gallick, Gary E.
    Efstathiou, Eleni
    Troncoso, Patricia
    Logothetis, Christopher
    CLINICAL CANCER RESEARCH, 2020, 26 (05) : 990 - 999
  • [7] Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer
    Simons, JW
    Carducci, MA
    Mikhak, B
    Lim, M
    Biedrzycki, B
    Borellini, F
    Clift, SM
    Hege, KM
    Ando, DG
    Piantadosi, S
    Mulligan, R
    Nelson, WG
    CLINICAL CANCER RESEARCH, 2006, 12 (11) : 3394 - 3401
  • [8] Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study
    Tombal, Bertrand
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppel, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufi K.
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew R.
    LANCET ONCOLOGY, 2014, 15 (06): : 592 - 600
  • [9] Enzalutamide monotherapy: One-year extended follow-up of a phase 2 study in hormone-naive prostate cancer patients.
    Tombal, Bertrand F.
    Borre, Michael
    Rathenborg, Per
    Werbrouck, Patrick
    Van Poppet, Hendrik
    Heidenreich, Axel
    Iversen, Peter
    Braeckman, Johan
    Heracek, Jiri
    Baskin-Bey, Edwina
    Ouatas, Taoufik
    Perabo, Frank
    De Phung
    Hirmand, Mohammad
    Smith, Matthew Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer
    Lilleby, Wolfgang
    Gaudernack, Gustav
    Brunsvig, Paal F.
    Vlatkovic, Ljiljana
    Schulz, Melanie
    Mills, Kate
    Hole, Knut Hakon
    Inderberg, Else Marit
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (07) : 891 - 901
12345